IRIS
CANTINI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.697
AS - Asia 1.156
EU - Europa 912
SA - Sud America 208
AF - Africa 106
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 5.085
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.649
SG - Singapore 430
VN - Vietnam 225
CN - Cina 222
RU - Federazione Russa 179
BR - Brasile 162
IT - Italia 160
HK - Hong Kong 124
DE - Germania 105
IE - Irlanda 91
SE - Svezia 82
GB - Regno Unito 67
FI - Finlandia 63
FR - Francia 59
CI - Costa d'Avorio 55
IN - India 39
CA - Canada 30
UA - Ucraina 26
MA - Marocco 21
PL - Polonia 19
JP - Giappone 18
BD - Bangladesh 16
MX - Messico 14
AR - Argentina 13
ZA - Sudafrica 13
IQ - Iraq 12
BE - Belgio 11
CO - Colombia 10
NL - Olanda 10
TR - Turchia 10
PH - Filippine 9
PK - Pakistan 8
CZ - Repubblica Ceca 7
EC - Ecuador 7
UZ - Uzbekistan 7
EG - Egitto 6
ID - Indonesia 6
DK - Danimarca 5
ES - Italia 5
AT - Austria 4
IL - Israele 4
KR - Corea 4
RO - Romania 4
SA - Arabia Saudita 4
VE - Venezuela 4
CL - Cile 3
EU - Europa 3
NP - Nepal 3
TN - Tunisia 3
UY - Uruguay 3
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
CH - Svizzera 2
DZ - Algeria 2
HN - Honduras 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LT - Lituania 2
OM - Oman 2
PY - Paraguay 2
TH - Thailandia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
GR - Grecia 1
GY - Guiana 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
LY - Libia 1
MK - Macedonia 1
MR - Mauritania 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
PR - Porto Rico 1
RS - Serbia 1
SI - Slovenia 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZM - Zambia 1
Totale 5.085
Salva come PNG Salva come JPEG
Città #
Ashburn 544
Singapore 321
Chandler 265
Des Moines 241
San Jose 138
Dallas 126
Hong Kong 121
Fairfield 96
New York 95
Dublin 85
Boardman 84
Munich 75
Ho Chi Minh City 65
Beijing 60
Abidjan 55
Los Angeles 55
Hanoi 54
Ann Arbor 51
Wilmington 45
Seattle 43
Woodbridge 39
The Dalles 35
Turku 35
Houston 34
Jacksonville 34
Cambridge 32
Lauterbourg 32
Lawrence 31
Princeton 31
Santa Clara 29
Turin 29
Buffalo 27
Helsinki 27
Moscow 26
San Mateo 25
San Diego 24
Chicago 23
Warsaw 19
London 18
Rome 18
Da Nang 16
Montreal 16
Pune 16
Washington 15
São Paulo 14
Ancona 13
Orem 13
Atlanta 12
Johannesburg 12
Tokyo 12
Brussels 11
Council Bluffs 11
Denver 11
Hefei 11
Boston 10
Haiphong 10
Baghdad 9
Poplar 9
Salt Lake City 9
Shanghai 8
Rio de Janeiro 7
Tashkent 7
Urbisaglia 7
Amsterdam 6
Biên Hòa 6
Mexico City 6
Olomouc 6
Redmond 6
Shenzhen 6
Stockholm 6
Brasília 5
Brooklyn 5
Chennai 5
Columbus 5
Elk Grove Village 5
Falls Church 5
Manchester 5
Ninh Bình 5
Nuremberg 5
Tolentino 5
Wuhan 5
Zhengzhou 5
Arnold 4
Belo Horizonte 4
Bến Tre 4
Can Tho 4
City of London 4
Fortaleza 4
Frankfurt am Main 4
Guangzhou 4
Istanbul 4
Medellín 4
Mumbai 4
Phoenix 4
Porto Alegre 4
Qualiano 4
Điện Bàn 4
Bắc Ninh 3
Calgary 3
Charlotte 3
Totale 3.617
Salva come PNG Salva come JPEG
Nome #
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 199
Are liver nested stromal epithelial tumors always low aggressive? 198
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 190
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 188
Optimal management of resected gastric cancer 179
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 168
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 166
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 165
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 165
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 161
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 161
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 157
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 146
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 140
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 138
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC 136
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 135
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 130
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 130
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience 127
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 125
Cancer patient perspective in the arena of COVID-19 pandemic 125
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 122
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 121
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study 116
Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: an optical coherence tomography angiography study 116
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study 113
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 111
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 108
Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients' 105
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients 104
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 101
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy 89
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 88
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 84
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078] 84
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 79
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 76
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 67
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 66
Feature Engineering Assessment of Tumor Infiltrating Lymphocytes in Lung Adenocarcinoma 5
Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors 2
Totale 5.186
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.287
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.287
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021107 0 0 0 0 0 0 0 0 0 20 51 36
2021/2022276 3 26 5 6 17 34 13 15 48 16 36 57
2022/2023853 53 88 39 67 42 284 0 43 139 8 71 19
2023/2024405 67 9 28 32 48 127 2 8 0 17 5 62
2024/2025921 148 75 38 18 39 51 74 38 156 41 116 127
2025/20262.318 202 135 135 268 363 193 414 228 204 176 0 0
Totale 5.186